Additional file 2: of Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimerâ s disease: results of a randomized, double-blind, placebo-controlled phase 2a study

Table S1. Summary statistics and treatment effects of CSF, EEG, (RSf)MRI and cognition parameters. Difference (delta) plus 95% CI between treatment groups at EOT, controlled for baseline, age, gender, ApoE and country. Negative Cohenâ s D indicates lower values at EOT in PQ912 group (less increase or more decrease). (PDF 89 kb)